Current Clinical Trials

High risk, localized prostate cancer: Current trials for men with high-risk localized prostate cancer study treatment given before surgery. This includes studies of treatment with docetaxel and other drugs. Click here for more information.
Hormone-refractory prostate cancer: Current trials for men with hormone-refractory prostate cancer includes studies of the Duke Docetaxel Predictor, the drug RAD001, and a biopsy program. Click here for more information.

Early stage NSCLC: The first current trial for men and women with early stage NSCLC is a study of dasatinib treatment. This trial is open to men and women recently diagnosed with early stage NSCLC. It studies if dasatinib treatment given before surgery can reduce the size of NSCLC tumors. Click here for more information.; The second current trial for men and women with early stage NSCLC is a study of genomic profiles for the chemotherapy agents vinorelbine and pemetrexed. Click here for more information.
Late stage NSCLC: The current trial for men and women with late stage NSCLC is a study of genomic profiles and their ability to predict resistance and sensitivity to platinum chemotherapy. Click here for more information.

Clinical Trial Timeline

	2007	2008	2009	2010	2011	2012
Clinical Study
Prostate Cancer — docetaxel in hormone refractory prostate cancer
Non-small cell lung cancer — neoadjuvant dasatinib, stages IB & II
Non-small cell lung cancer = previously treated patients
Non-small cell lung cancer – advanced, stages select IIIB & IV
NSCLC adjuvant cisplatin w/vinorelbine or pemetrexed: IB, II, & IIIA
Non-small cell lung cancer – Lung Metagene Score, stage I
Breast cancer — early stage
Prostate cancer — hormone refractory prostate cancer biopsy program
Metastatic (Solid Tumor)
Prostate cancer – high-risk, localized prostate cancer
Prostate cancer – RAD0001 in hormone refractory prostate cancer

Open Trials Future Trials